December 16, 2025 Is the era within which a TURP was performed associated with differences in reoperation rates, specific surgical side effects, or the requirement for BPH medicat ...
Antioxidants for Male Infertility: Therapeutic Scheme and Indications. A Retrospective Single-Center Real-Life Study - Beyond the Abstract ...
Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...
Is Primary Retroperitoneal Lymph Node Dissection the Way Forward for Patients with Testicular Seminoma and Limited Retroperitoneal Metastases? - Beyond the Abstract ...
Read the Full Video Transcript Alicia Morgans: Hi. I'm so excited to be here at ASCO GU 2024, where I am speaking with Dr. Alan Bryce, who is the Chief Clinical Officer of City of Hope, Arizona, which ...
Reno, Nevada (UroToday.com) – Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technologies for use in interventional urology, today ...
Read the Full Video Transcript Neeraj Agarwal: Welcome to UroToday. Today we have Dr. Arun Azad, Associate Professor and a medical oncologist specializing in genitourinary cancers at the Peter ...
(UroToday.com) In this presentation, Dr. Chi presented the results of the MAGNITUDE study. MAGNITUDE is a randomized phase 3 study of abiraterone acetate and prednisone (AAP) plus niraparib (NIRA) or ...
The ideal treatment for Peyronie’s disease should be safe, effective, and noninvasive. H100™ is the first treatment option to possibly achieve these goals. H100 is shown to be safe, with mild rash as ...
Alicia Morgans discusses a study with Stacy Loeb, exploring the impact of a plant-based diet on prostate cancer survivors, based on Loeb's paper published in Cancer. Dr. Loeb, motivated by clinical ...
Read the Full Video Transcript Alicia Morgans: Hi, I am so excited to be here with Professor Oliver Sartor, who's joining me from the Mayo Clinic, and also joining me from a recent presentation that ...
Neeraj Agarwal is joined by Arun Azad to discuss preliminary findings from the LIBERTAS trial. This de-escalation study in metastatic hormone-sensitive prostate cancer gives patients six months of ADT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback